Opko Health, Inc. (NASDAQ:OPK) traded with the volume of 8.36 Million Yesterday. The Stock Opened its session at $9.84 and closed at $9.91 by showing an decrease of -4.99 percent. Opko Health, Inc. has 1 year price target of 15.25. The stock gained a consensus recommendation of 1.8 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The company is expected to report its next EPS (earnings per share) on Nov 07 AMC. The company reported its last quarter on Jun 16.
The 5 analysts offering 12-month price forecasts for OPKO Health Inc have a median target of 16.00, with a high estimate of 22.00 and a low estimate of 10.00. The median estimate represents a +61.45% increase from the last price of 9.91. (CNN MONEY)
Many Analysts provided their foresight on Revenue Estimates of Opko Health, Inc. where they believe that the company has the potential to earn average revenue of $319.64 Million for the current quarter. According to their predictions High & Low revenue estimates are 328.8 Million and 310.2 Million respectively.
Opko Health, Inc. (NASDAQ:OPK) topped its 52-week high price of $11.85 on Mar 22, 2016 and 52-Week Low Price of $7.12 on Jan 20, 2016. The Stock currently has the market capitalization of $5.74 Million, P/E (price to earnings ttm) of 38.12 and Weekly volatility of 2.58%% and monthly volatility of 2.60%% respectively.
Opko Health, Inc. Gross Margin percentage stands at 52.1% while its Operating Margin for trailing twelve month is -1.4 percent and Profit margin (ttm) is 12.5 Percent. The stock is currently moving above its 20-Day Simple Moving Average of -1.33% with the 50-Day Simple Moving Average of -1.33 percent. Currently, the company has SMA200 (200-day simple moving average) of 1.24 Percent. The Stock has YTD (year to date) performance of -1.39 percent.
Many research firms have provided their ratings on Opko Health, Inc. (NASDAQ:OPK) where Standpoint Research provided Buyrating on the stock on 3-Jun-16. Other firms include JP Morgan giving Overweight rating on 16-Oct-15.
The latest Insider trade was made on 5 Oct 2016 where PHILLIP FROST ET AL Chief Executive Officer did a transaction type “Buy” in which 225 shares were traded at a price of $10.57. Another insider trade includes Chief Executive Officer PHILLIP FROST ET AL who also initiated a transaction in which 2400 shares were traded on 5 Oct 2016 as “Buy”.
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.